Liver Fibrosis in MASLD: A Key Driver of Heart Disease Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD), the updated terminology for what was previously known as non-alcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver condition globally, affecting a significant portion of the adult population, with estimates exceeding 30%. The renaming to MASLD, officially adopted in 2023, reflects a deeper understanding of the disease's underlying metabolic origins and aims to reduce the stigma associated with the 'non-alcoholic' label. This critical shift in nomenclature helps emphasize that the condition is driven by metabolic dysregulation, including factors like obesity, insulin resistance, type 2 diabetes, and dyslipidemia. A key finding highlighted by recent research, including the article in question, is the strong and often underestimated link between MASLD and an increased risk of cardiovascular disease (CVD). In fact, cardiovascular disease is consistently identified as the leading cause of mortality among individuals with MASLD, surpassing liver-related complications such as cirrhosis or hepatocellular carcinoma. This underscores MASLD not merely as a liver disorder but as a systemic condition with profound cardiometabolic implications. The article's focus on "Fibrosis-Driven Cardiovascular Risk" is particularly pertinent and well-supported by the latest scientific evidence. Studies have increasingly shown that the severity of liver fibrosis – the scarring of liver tissue – is a stronger predictor of cardiovascular outcomes in MASLD patients than the mere accumulation of fat (steatosis). Individuals with advanced fibrosis exhibit significantly higher rates of cardiovascular events and mortality, independent of traditional cardiovascular risk factors. This emphasizes that as the liver disease progresses and liver scarring worsens, the risk to the cardiovascular system escalates considerably. The mechanisms linking liver fibrosis to heightened cardiovascular risk are complex and involve shared metabolic, inflammatory, and fibrotic pathways. MASLD contributes to systemic low-grade inflammation, oxidative stress, insulin resistance, and atherogenic dyslipidemia, all of which accelerate the development and progression of atherosclerotic cardiovascular disease (ASCVD). Atherosclerotic cardiovascular disease, characterized by the buildup of plaque in arteries, leads to serious conditions like coronary artery disease, heart attacks, strokes, and heart failure. The emerging links between MASLD and ASCVD are now widely recognized, with MASLD being considered an independent risk-enhancing factor for ASCVD by leading health organizations. This recognition calls for a more integrated approach to patient care, where liver disease assessment, especially fibrosis evaluation, is incorporated into cardiovascular risk stratification to better identify high-risk individuals and implement comprehensive cardiometabolic management strategies. For an Indian audience, this news holds significant relevance. India is grappling with a high and increasing prevalence of metabolic disorders, including obesity and type 2 diabetes mellitus (T2DM), which are primary drivers of MASLD. Recent studies, such as the Phenome India cohort, indicate that MASLD affects a substantial proportion of the adult population in India, with estimates suggesting nearly 40% of participants could be affected, and rates even higher among those with T2DM (up to 70%). This makes the link between MASLD, fibrosis, and cardiovascular disease a critical public health challenge for the country. The silent progression of MASLD, often asymptomatic in its early stages, coupled with its strong association with prevalent cardiometabolic risk factors, poses a significant burden on India's healthcare system. Early detection and multidisciplinary management, focusing on lifestyle modifications, aggressive management of metabolic risk factors, and regular assessment of liver health, are crucial to mitigate the rising incidence of cardiovascular complications in the Indian population. The importance of this scientific article lies in reinforcing the need for clinicians across specialities to be aware of these interconnected diseases and work collaboratively to improve patient outcomes.

Frequently Asked Questions

Read Full Story on Quick Digest